A trade association of independent service organizations is claiming that GE Medical Systems of Milwaukee has acquired equipment maintenance firm Serviscope of Wallingford, CT. The group believes that the acquisition represents one more blow to
A trade association of independent service organizations is claiming that GE Medical Systems of Milwaukee has acquired equipment maintenance firm Serviscope of Wallingford, CT. The group believes that the acquisition represents one more blow to competition in the equipment maintenance market.
The likelihood of a GE/Serviscope deal was raised in public comment documents filed by the Independent Service Network International of Atlanta regarding GEs acquisition of another ISO, InnoServ Technologies of Arlington, TX. In the documents, ISNI officials state that Serviscope executives told the ISNI that GE acquired their firm in late August. Serviscope is a member of ISNI.
If the acquisition did occur, it would represent another step in the consolidation of the ISO market by removing one of the few companies remaining that is able to offer multivendor service. Representatives from Serviscope and GE were unavailable for comment as of press time.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.